AstraZeneca (LSE:AZN) Gains EU Approval For Breast Cancer Treatment DATROWAY

AstraZeneca (LSE:AZN) saw its share price decline by 3.5% in the last quarter, a period marked by several key developments, including the European approval of DATROWAY for breast cancer treatment and Imfinzi in non-small cell lung cancer. Despite these approvals, which could positively impact long-term prospects, broader market volatility weighed on the company's performance. Notably, President Trump's tariff threats against pharmaceutical companies likely added further pressure, as the entire sector faced declines. While other major indexes and stocks experienced significant swings due to trade war uncertainties, AstraZeneca's performance aligned with broader market trends, reflecting general economic and industry pressures.

We've identified 2 weaknesses for AstraZeneca that you should be aware of.

The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

The recent developments concerning AstraZeneca, particularly the European approval of DATROWAY and Imfinzi, represent significant milestones with the potential to impact future revenue positively. Despite this, the company's share price retraction of 3.5% in the last quarter highlights the overarching influence of broader market volatility and trade tensions. The impact on forecasted revenue and earnings may be shaped by these approvals, which, if successful in the market, could offset some of the ongoing pricing and competition challenges outlined in the analysts' assessments.

Over the last five years, AstraZeneca's total return, accounting for both share price appreciation and dividends, was 53.12%, illustrating considerable long-term growth in shareholder value. However, the five-year return dwarfs the recent one-year performance, where the company merely aligned with the UK market's 3% decline. This contrast underscores the pressures faced by the pharmaceutical sector amidst geopolitical and economic uncertainties.

While the current share price stands at £112.28, the consensus analyst price target suggests a potential upside of 20.1%, reflecting a more optimistic outlook over the medium term. Analysts anticipate notable earnings and revenue growth as AstraZeneca continues to execute its pipeline strategy, targeting 20 new medicines by 2030. The ongoing development efforts and expected Phase III trial readouts in 2025 could support these projections, although potential challenges such as pricing pressures and market competition lurk as formidable risks.

Upon reviewing our latest valuation report, AstraZeneca's share price might be too pessimistic.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com